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One of the most important but most difficult goals of cancer biology has been
to demonstrate the existence of tumor-specific antigens . The first strong evidence
fortheirexistence was obtained about 30 years agofrom transplantation studies using
chemically induced fibrosarcomas of mice (1-5) . But despite decades of extensive
research, there is still no convincing molecular evidence forthe existence of tumor-
specific antigens, i.e., formolecules that are recognized by the immune system and
encoded by tumor-specific mutant genes not present in nonmalignant cells . The
identification of these antigens has been hampered by the lack of control cells from
the host from which thetumor wasobtained and by thelack ofcloned probes specific
for the putative tumor antigens . The fact that cloned immunological probes have
been generated foronly a fewtumors suggests the possibility that the particular tumors
may have arisen in mice not fully syngeneic with mice from which nonmalignant
control cells were obtained, i.e ., the assumed tumor antigens (6-8) may have been
alloantigens (9).
In the present paper we have, therefore, derived UV light-induced and sponta-
neous mouse tumors, and we have isolated from each original tumor-bearing an-
imal nonmalignant cells and DNA. We were successful in consistently generating
cloned immunological probes to alarge number of these tumors . These probes did
not react with normal autologous control cells, but showed exquisite specificity for
the tumor used for immunization . These tumors, immunological probes, and con-
trol materials will, therefore, allow areliable search fortumor-specific mutant genes
encoding tumor-specific antigens .
Materials and Methods
Mice.
￿
5-10-wk-old germ free-derived, pathogen-free femaleC3H/HeNmammarytumor
virus-negative (MTV-),' BALB/cAnN or nude NCR/Nu mice were purchased from the Na-
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' Abbreviations used in this paper: CRPMI, complete RPMI ;MTV-, mammary tumor virus-negative;
MLTC, mixed lymphocyte tumor cell culture .
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tional Cancer Institute, Frederick Cancer Research Facility Animal Production (Frederick,
MD), and were maintained in laminar flow units as described (10). The original stock of
nude C3H mice was in its 23rd backcross generation when obtained from a colony at the
Biology Division of the Oak Ridge National Laboratory, Oak Ridge, TN .
Derivation of Tumor Bank.
￿
The general method for induction of tumors in mice with UV
light has been described (11). Briefly, the backs of 4-5-mo-old mice were shaved weekly and
exposed three times per week to a source ofUV light consisting of a bank of six Westinghouse
FS40 sunlamps mounted in parallel 10.5 cm apart and 20 cm above the bottoms of the animal
cages (see footnote to Table I). A colony of >2-yr-old C3H/HeN (MTV- ) mice was main-
tained for the appearance of spontaneous tumors. Induced or spontaneous tumors were ex-
cised from the original host under sterile conditions and fragments were (a) placed in vitro
for establishing a tumor cell line, (b) transplanted into syngeneic nude and normal mice to
determine growth behavior in vivo, and (c) stored in liquid nitrogen for reference and for
obtaining DNA from the original tumor. Cells and DNA from nonmalignant tissue were
isolated from each tumor-bearing host.
Tumor cells were adapted to growth in vitro by adding finely minced tumor fragments
to culture flasks containing MEM (410-1100; Gibco Laboratories, Grand Island, NY) sup-
plemented with 10% FCS (29-161-54; Flow Laboratories Inc., McLean, VA), 1% peni-
cillin/streptomycin (600-5140; Gibco Laboratories), 1% gentamycin (600-5750AD; Gibco
Laboratories), and lo7o nystatin (600-5340; Gibco Laboratories). Fibroblasts from the heart
and lungs of each tumor-bearing mouse were established. Briefly, the heart and lungs were
removed en bloc, minced with scissors and placed in MEM supplemented as outlined above.
Flasks with adapted tumor cells or normal fibroblasts were usually subconfluent with cells
within 1-2 wk ofculture, and cells were then frozen in liquid nitrogen to allow later reference
to the first culture of the original tumor or normal tissue. DNA was extracted from single
cell suspensions of normal spleen and kidney tissues from each host; cells prepared with a
glass tissue grinder were lysed with 2% SDS in 0.4 M EDTA and DNA was extracted using
standard procedures (12). For use in experiments, aliquots ofthe original tumor cell or fibroblast
batch were expanded in vitro for ti2 wk and cryopreserved in aliquots. Whenever tumor cells
were required for experiments, aliquots were thawed and used 24-48 h later without further
passage.
Tumor Transplantation.
￿
For tumor challenge an equal number (3-6) of I-mm3 tumor frag-
ments were implanted subcutaneously with a trocar into one inguinal region of nude and
normal mice. The nude mice were always injected last to verify that the tumor tissue re-
mained viable until the end of the transplantation procedure. When transplanted into young
syngeneic mice, strongly immunogenic tumors grow during the first 10 d and then regress.
These tumors can grow, however, in nude or immunosuppressed mice (13) and eventually
kill these animals by infiltrative growth without macroscopic evidence of distant metastases.
Generation of CTL.
￿
For immunization with UVinduced regressor tumors, mice were im-
munized either subcutaneously with tumor fragments, or intraperitoneally with 10' tissue
culture cells. For immunization against poorly immunogenic spontaneous tumors, mice were
immunized intraperitoneally two to four times with 10' irradiated (10,000 rad) tumor cells
at 2-wk intervals. Extensive preliminary experiments showed that the following procedure
and culture conditions, modified from a previously described method (10), were most consis-
tently successful for generating CTL to the various tumors used. 10 d after immunization,
spleens were removed from immune animals and 8 x 106 immune spleen cells were restimu-
lated in 6-d mixed lymphocyte tumor cell cultures (MLTC) with 4 x 104 mitomycin
C-treated tumor cells in 3 ml of RPMI 1640 (430-1800; Gibco Laboratories), supplemented
with 10°Jo FCS, 1% penicillin/streptomycin, and 5 x 10-'M 2-ME (CRPMI). Cultures were
prepared in upright 16 x 125 mm round-bottomed tissue culture tubes (3033 ; Falcon Lab-
ware, Becton Dickinson & Co., Lincoln Park, NJ), which were found to be superior to up-
right culture flasks. We select lots of FCS that do not induce lymphocytes with promiscuous
cytolytic activity, but do support the growth of specific T cells; at least four different lots
of FCS have worked in the past (selected from -20 lots tested). Long-term CTL lines and
clones were maintained by passage in Vbottomed 96-well microtiter plates (76-223-05; Linbro,
McLean, VA) at 37°C and 5% C02 in a fully humidified incubator using a modificationWARD ET AL.
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of a previously described method (14). T cells from several wells were pooled and counted.
Irradiated (2,000 rad) Syngeneic fillers were added at a 1 :100 ratio of T cells to filler cells.
The mixture was washed, and mitomycin C-treated tumor cells were added as stimulators
at a 10:1 responder-to-stimulator ratio in CRPMI supplemented with 33% (vol/vol) super-
natant from a secondary MLC as a source ofT cell growth factor (15, 16). The cell suspension
was then dispensed in 0.2-ml aliquots per well containing 104 T cells, 103 stimulators, and
106 filler cells. Specific CTL were cloned by limiting dilution in flat-bottomed microculture
wells (76-003-05 ; Linbro) and aliquots were stored in liquid nitrogen as a permanent refer-
ence. Briefly, aliquots of 106 CTL in CRPMI containing 15-20% FCS and 10% DMSO were
placed on ice for 30 min before transfer to a -80'C freezer overnight and long-term storage
in liquid nitrogen. Frozen cells were recovered by culturing cells at an increased density (2
x 104 CTL/well) and then passaged as outlined above.
s1Chromium-release Assay.
￿
Cytotoxicity of CTL was determined in a 4-6 h "chromium-
release assay as previously described (17). The percentage of specific lysis was calculated by
the formula: percent specific lysis = 100 x [(experimental release - spontaneous release)/(total
release - spontaneous release)] . Spontaneous release was always 25% ofthe totalmaximum
release and usually <15% . For some experiments, 30 U/ml of murine rIFN-1' (lot 4407-47;
1.97 x 10' U/mg; Genentech, South San Francisco, CA) was added to cultured cells 48 h
before their use as targets in a IIchromium-release assay. We have found that this dose of
IFN-y increases the level of expression of MHC class I antigens in tumors as determined
by FRCS analysis.
Generation ofmAbs.
￿
Syngeneic mAbs were generated by fusing SP2/0 mouse myeloma cells
(18) with spleen and lymph node cells from mice immunized with 107 irradiated (10,000 rad)
AG-104A tumor cells intraperitoneally, followed 1 mo later by a subsequent immunization
of 2 x 106 tumor cells intravenously. The fusion was done 3 d after the intravenous boost.
Supernatants of growing hybrids were screened by FAGS IVB analysis (Becton Dickinson
& Co., Mountain View, CA) for reactivity with the immunizing tumor (AG-104A) and con-
trol tumors. Tumor cells were first incubated with supernatants from growing hybrids fol-
lowed by incubation with fluorescein-coupled goat anti-mouse Ig. The binding ratio was de-
termined as the amount of fluorescence after staining with both antibodies, divided by the
amount offluorescence afterstaining with the second antibody alone. Hybridomas secreting
specific mAb were cloned in soft agar (19), expanded in tissue culture, and stored in liquid
nitrogen.
Selection ofAntigen Loss Variants In Vitro.
￿
Tumor cells (2-3 x 106) in 20 ml CMEM were
added to 75-cm2 tissue culture flasks that were incubated at 37°C for 3 h to allow cells to
attach. CTL were added to the flaskat an E/T ratio of 1 :1 . 24 h later, medium was aspirated
from the flaskto remove most of the CTL and killed tumor cells, and was replaced with fresh
CMEM. After 2-3 wk, the flaskwas N50-75% confluent and was retreated with CTL. Three
to four selections were necessary to ensure stability of the variant phenotype. Variant cell
lines were then cloned, expanded, and cryopreserved.
Results
Transplantation Characteristicsof UV-induced andSpontaneous Tumors.
￿
During the years
of 1983 to 1987, five series of UV-induced or spontaneous tumors were isolated as
outlined in Materials and Methods. We first determined whether these newly iso-
lated tumors were as immunogenic as UV-induced tumors that have been previ-
ouslydescribed (20). Indeed, we observed that a significant percentage ofUV-induced
tumors in C3H mice (44-78%), and BALB/c mice (19%) were rejected by normal
mice but grew in nude mice (Table I). These results are consistent with the previous
observation that primary UV-induced tumors of C3H/HeN (MTV-) mice exhibited
a greater degree of antigenicity or a greater percentage of regressor tumors than
those of BALB/cAnN mice (11) . To establish whether these transplantation charac-
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TABLE I
Transplantation Characteristics of 121 UV-induced and 7 Spontaneous Tumors
that Have Been Isolated with Autologous Normal Control Cells
For induction of tumors of the 4000 and 5000 series, mice were irradiated for 1 h three times per week
on a Monday, Wednesday, Friday schedule until a tumor of a sufficient size (-10 mm diameter) deve-
loped. For tumors of the 6000 series, mice were irradiated 1 h three times per week for 15 wk and then
30 min three times per week for 6 wk. All mice developed tumors between 20 and 40 wk after start of
UV irradiation. A total of 121 UV-induced tumors were isolated from 93 mice (28 mice had 2 to 3 tumors)
and 7 spontaneous tumors were isolated from 6 mice (1 mouse had 2 tumors) .
t Three 1-mms fragments of each original primary tumor were implanted subcutaneously into one nude and
three normal mice (first transplantation, see Materials and Methods). Tumors were reisolated from the
nude mice and subsequently transplanted into a second nude mouse and three additional normal mice (se-
cond transplantation, also see Fig. 1).
plantation, we reisolated the tumors of the first transplant generation from thenude
mice and transplanted them again into normal syngeneic and nude mice (Fig. 1
and Table I). At this second transplantation, 35 tumors were rejected by all of the
normal mice, and 5 additional tumors were rejected by 2 of the 3 normal mice chal-
lenged. These 40 tumors were defined as "stable repressors." "Unstable repressors"
were defined as tumors that grew in the majority of mice at the second transplant
generation when transplanted tissue from the nude rather than the original tumor
was used . Testing of 31 of the "stable regressors" in 1-4 subsequent transplantation
experiments showed that 27 of these tumors continuedto be rejected by the majority
of normal mice. 17 of the "unstable repressors" that had showed progressive growth
behavior in the second transplantation maintained this phenotype when similarly
tested in subsequent transplantation experiments. In some instances, it was attempted
to break the resistance of normal mice to challenge with these regressor tumors by
injectingincreasing numbersof tumor fragments. However, even the largest numbers
of tumor fragments, e.g., >20 1-mm' fragments transplanted subcutaneously were
rejected by normal mice. Thus, as far as we could test, regressor tumors that had
a stable regressor phenotypeseemed to be as immunogenic as the UVinduced tumor
1591-RE (21) we had previously studied (10). In fact, upon several occasions we have
tried to derive in vivo progressor variants from these regressor tumors, and found
that these variants were as infrequent as we had previously observed in the UV
induced tumor 1591 (10). Progressor tumors usually grow in two-thirds or more of
normal mice. All of the spontaneous tumors grew in normal mice in the first trans-
plant generation consistent with the previously reported lower immunogenicity of
spontaneous tumors (2, 3). For example AG-104A, one of the tumors we tested ex-
tensively, grows progressively at a dose as low as 104 cells. Multiple tumors (up to
Mode of tumor
induction"
Designation
(series) Strain
Year of
experiment
Growth behavior in normal micet
Regressor phenotype Progressor
Stable (7o) Unstable (%) phenotype
Ultraviolet light UV-(4000) C3H/HeN (1983-84) 4 (45) 3 (33) 2 (22)
UV-(5000) BALB/cAn (1984-85) 5 (19) 0 (0) 22 (81)
UV-(5000) C3H/HeN (1984-85) 0 (0) 4 (44) 5 (56)
UV-(6000) C3H/HeN (1986-87) 31 (41) 19 (25) 26 (34)
Unknown (spon-
taneous aging) AG-(100) C3H/HeN (1983-86) 0 (0) 0 (0) 7 (100)
Total 40 26 623) were observed in several (28/93) of theUVirradiated mice and inone ofthe mice
developing spontaneous tumors as has been observed previously in UV-irradiated
(12) and aging normal MTV-C3H mice (22) . However, with regard to immunoge-
nicity, these tumors showed the same distribution pattern as that observed in mice
developing single tumors . Similarly, there was no apparent correlation between histo-
logic type and immunogenicity of the tumors, even though some tumors appeared
to be squamous cell carcinomas, while othershad the appearance ofundifferentiated
spindle cell tumors . The latter histologic type appears to be acommon final pattern
ofavarietyoftumors often inappropriately referred to by experimental pathologists
as fibrosarcomas irrespective ofwhether thetumors were ofmesenchymal or epithe-
lial origin . Recent histochemical studies suggested that >95% of UV-induced mu-
rine tumors of the C3H strain are squamous cell carcinomas (23), but we have not
yet analyzed our recently induced tumors with keratin-specific probes .
Individual Tumor Specificity ofCTL-definedAntigens on UVinducedRegressor Tumors.
￿
The
UV light-induced regressor tumors were used as immunogens to generate cytolytic
T cell clones . Fig . 2 indicates that each of three tumors tested elicited CTL that
killed only cells used for immunization but not cells of the other tumors . The other
tumors could be used, however, to elicit their own specific CTL . Since the degree
of diversity ofCTL-defined antigens had not been rigorously analyzed in the past,
we determined next how commonly the same CTL-defined epitope is expressed by
tumors of independent origin . Fig. 3 showsthat aCTLclone raised againstthe C3H-
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FIGURE 1 .
￿
Types ofgrowth behavior ofUVinduced or
spontaneous tumors when transplanted into normal mice
andT cell-deficient nude mice (also see Table I) .
FIGURE 2 . Specificity of CTL clones
generated in reciprocal experiments to
three differentUV-induced tumors. Each
ofthese C3Htumors elicitsCTL that are
specific for thetumorused for immuniza-
tion and do not lyse cells of the other two
tumors in a 4.5-h 5I Cr-release assay.222 TUMOR ANTIGENS DEFINED BY CLONED IMMUNOLOGICAL PROBES
derived UV6138 regressor tumor killed UV6138 tumor cells but not cells of any
of theother 25 tumors tested . Similar resultswere obtained usingaCTL clone specific
for the BALB/cAnN-derived UV-induced regressor tumor UV-5117 (Fig . 4 a) and
usinganotherCTLclone specific forthe C311-derived UV-induced regressor tumor
UV-6130 (Fig. 4 b) . In several instances, two or more tumors arose in UV-irradiated
animals . This allowedus to test whether tumors originating in the same animal dis-
played different antigenic specificities . Fig . 5, a and b, shows that anti-UV-6132A
CTL didnot kill UV-6132B tumor cells while in the reciprocal experiment anti-UV-
6132B CTL did not kill UV-6132A tumor cells . Furthermore, anti-UV-6139B CTL
(Fig . 5 c) did not kill either of the other two tumors that arose in the same mouse .
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FIGURE 3 .
￿
Uniqueness ofaCTL-defined an-
tigen on the UV-induced tumor 6138 . None
of 25 other syngeneic C3H tumor cell lines
are lysed by this CTL clone in a 4.5-h 5tCr-
release assay.
FIGURE 4 .
￿
Generality ofthe finding that unique tumor an-
tigens are expressed in UV-induced tumors . (a)Unique an-
tigens are also detected in a UV-induced tumor of another
strain, BALB/cAnN ; (b) a second C3H tumor tested ex-
presses such antigens in addition to the one analyzed in
Fig. 3 . Targets were tested in a 4.5-h 51Cr-release assay.
FIGURE 5 .
￿
Multiple tumors isolated from a single
host have individually distinct CTL-defined an-
tigens . All five tumors are poorly differentiated
spindle cell tumors of very similar histologic ap-
pearance . (a, b) Tumors UV-6132A andUV-6132B
were isolated from one individual mouse . (c)
Tumors UV6139A,B and C were isolated from
one individual mouse . Targets were tested in a
4.5-h SICr-release assay.All of these five tumors are poorly differentiated spindle cell tumors of very similar
histologic appearance.
CTL Clones Reactive with Unique TumorAntigens Do NotLyse Nonmalignant Autologous
Control Cells. The above experiments showing that multiple tumors arising in the
same animal have individual antigenic specificities areconsistent with previous trans-
plantation assays (24) that have been taken to suggest that the unique tumor an-
tigens could not be due to genetic impurity in the mouse strain. However, because
of the genetic instability of cancer cells (25), genes encoding an alien antigenic
specificity (8)couldbe lost during continuous tumorgrowth, particularly when tumors
are serially transplanted in immunocompetent mice (10, 11, 26). Therefore, we also
tested whether CTL clones with unique tumor specificity would kill nonmalignant
fibroblasts derived from the same mouse that gave rise to the tumor. Fig. 6 (a, b,
d, e, f h) shows that none of six CTL clones killed autologous normal fibroblasts.
Cytolytic effector T cells generated in MLTCs against two other tumors (Fig. 6,
c, g) also did not lyse autologous normal fibroblasts. The resistance of the normal
fibroblasts was not reversed by pretreatment of the target cells with IFN-y (Fig. 6
h and Table II) at doses that increased the level of MHC class I expression at least
fivefold (data not shown). However, all of eight autologous fibroblast lines tested
could clearly be lysed by an anti-H2' alloreactive CTL line (Table II) indicating
that the nonmalignant fibroblasts were not inherently resistant to the lytic mecha-
nism by which CTL kill target cells. Four of the eight effector populations (Fig. 6)
were analyzed for surface phenotype and were found to be CD8+ (data not shown).
ASingleMalignant Cell Can ExpressMultiple, Independent, Unique TumorAntigens.
￿
Using
the 1591 tumor model, we have previously found that a single malignant cell can
express multiple, unique tumor antigens (27). However, the CTL clones used for
this analysis may have detected alloantigens (such as minor histocompatibility an-
tigens), since autologous normal control cells were not available forthis tumor which
was later found to express two MHC class I molecules whose al and a2 coding se-
quencesare identical to those ofanothermouse strain (9). Therefore, we re-examined
the possibility that multiple, independent, unique antigens can be expressed by a
single malignant cell using asimilar approach as was used previously for such anti-
genic dissection (27), but with a tumor for which autologous normal fibroblasts are
available. Thus, the parental UV6139B tumor was used to generate cytolytic T cells
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FIGURE 6.
￿
AbsenceofCTL-defined tumor
antigens on autologous normal control
cells. (a-g) Untreated targets. (h) Tumor
and control cells were pretreated with 30
U/ml IFN-.y for 48 h before testing in a
4.5-h "Cr-release assay. (c andg) Effector
cells are from bulk cultures generated in
MLTCs(See MaterialsandMethods). In
all other panels, effector cells are from
cloned CTL lines.
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TABLE II
Autologous Nonmalignant Fibroblasts Are Killed by Alloreactive CTL
but not by Tumor-specific CTL
* 30 U/ml of murine rIFN-,y (lot 4407-47, 1.97 x 107 U/mg; Genentech, South
San Francisco, CA) was added to heart-lung fibroblast (HLF) cells 48 h be-
fore their use as targets. We have found that this dose of IFN-,y raises the level
ofexpression of MHC class I antigens (at least fivefold) as determined by FAGS
analysis.
The anti-H-2k CTL line of B10.D2 origin was generously provided by Dr.
Jeffrey Bluestone, Chicago, IL.
in an MLTC (Fig. 7 a) from which a CTL clone was isolated that was designated
anti-A (Fig. 7 b). This clone was used to select an antigen-loss variant resistant to
the anti-A CTL clone (Fig. 7 c) as described in Materials and Methods. This A -
antigen-loss variant was used to generate cytolytic T cells that killed the A- variant
as well as the parental UV6139B tumor cells (Fig. 7 d). A CTL clone with this reac-
tivity was designated anti-B (Fig. 7 e) and used to select a B- variant from the pa-
rental tumor (Fig. 7f). This B- variant still retained the A antigen (and, therefore,
had an A+B- phenotype) while the A- variant was still killed by the anti-B CTL
and, therefore, had an A-B+ phenotype (Fig. 8). The CTL used in these experi-
ments had unique reactivity with the UV-6139B tumor and did not lyse autologous
Targets IFN--y* E/T
Lysis of targets by
Tumor-specific CTL Anti-H-2kI CTL
6130 - 5:1 41 65
2 .5:1 33 63
6130 HLF + 5:1 - 2 36
+ 2 .5:1 - 2 26
- 5:1 ND 35
- 2 .5:1 ND 23
6132A - 5:1 39 22
- 2 .5:1 24 15
6132 HLF + 5:1 - 2 44
+ 2 .5:1 - 1 39
- 5:1 ND 49
- 2 .5:1 ND 40
6138 - 5:1 43 28
- 2 .5:1 33 27
6138 HLF + 5:1 0 31
+ 2 .5:1 0 27
- 5:1 ND 17
- 2 .5:1 ND 14
6139B - 5:1 61 63
- 2 .5:1 63 60
6139 HLF + 5:1 0 28
+ 2 .5:1 1 21
- 5:1 ND 8
- 2 .5:1 ND 7normal fibroblasts (Fig . 7) . Together, these experiments clearlyindicate thatasingle
tumor can express multiple, independent, unique tumor antigens .
A Spontaneous Tumoralso Expresses UniqueAntigens not Detected on Autologous Controls.
￿
Be-
causeof thehigh dosesofcarcinogen used to induce cancer in experimental animals,
unique tumor antigens could represent laboratory curiosities not observed when
cancers aretested that arose without deliberate exposure to carcinogens, i.e ., in tumors
that are thoughtby many investigators to more closelyresemble humancancer (28) .
Therefore, we tested whether CTL or antibody probes could detect on a sponta-
neous tumorunique tumor antigens that were absent from autologous normal con-
trol cells. The AG-104A tumor seemed to be particularly useful for such studies,
as two tumors arose independently in the same animal, allowing additional tests
for unique tumor specificity. As previously mentioned, this tumor like many other
spontaneous tumors, is poorly immunogenic, and therefore, it required multiple
immunizationsto elicit tumor-specific CTL. TheseCTLs were clearlytumor specific
in that they killed the AG-104A tumor, but not a second spontaneous tumor AG-
104B that arose in the same host, nor autologous normal control cells (Fig . 9) . Even
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FIGURE 7 .
￿
Generation of two different CTL clones reactive
to the.same tumor cell . ACTLclone (designated anti-A) against
the parental UV6139B tumor was generated (a, b) to select an
A- variant in vitro (c). This A- variant was then used as an
immunogen to generate an independentCTLclone (designated
anti-B; d, e) for selection of a B- variant from the parental UV
6139B tumor (f) . All targets were tested in a 4.5-h 51Cr re-
lease assay.
FicuRE 8 .
￿
Demonstration of independence of two
unique CTL-defined antigens expressed by a single
tumor cell . The A- and the B - variants show a
reciprocal sensitivity pattern to anti-A and anti-13
CTL clones, indicating that the A- variant had an
A-B' and theB- variant an A'B- phenotype . The
specificity of these CTL was analyzed in Fig . 7 .
Targets were tested in a 4.5-h "Cr-release assay.22 6 TUMOR ANTIGENS DEFINED BY CLONED IMMUNOLOGICAL PROBES
ANTI-AG-104A
1 .5 :1 6 :1 25 :1 1001
EHector-to-target ratio
FIGURE 9 .
￿
Unique tumor specificity ofcytolyticT cells
generated in an MLTC to the spontaneous tumorAG-
104A. Neithera second tumorfrom the same host nor
autologous fibroblasts are lysed in a4.5-h'ICr-release
assay.
though CTL with such specificity could be generated consistently in several inde-
pendent experiments, we were unable to establishCTL clones specific for thistumor
for reasons that are unclear. Interestingly, however, we did succeed in generating
an AG-104A-reactive hybridoma aftera single intraperitoneal injection ofC3N/HeN
mice with irradiated tumor cells and a single intravenous boost 3 d before fusion .
This hybridoma, designated PW237, secreted anIgG2amAb . Cytofluorometric anal-
ysis usinghybridoma supernatant showed that the antibody was specific fortheAG-
104A tumor (Fig . 10) . 25 other tumors that included UVinduced, MCA-induced,
FIGURE 10 .
￿
AmAb defines an antigen with unique tumor specificity on amurine tumor of spon-
taneous origin. The syngeneic mAb, PW237, did not react with a second spontaneous tumor
or autologous fibroblasts isolated from the same mouse, or 24 other syngeneictumors tested ir-
respective of whether they were UVinduced, MCA-induced, or of spontaneous origin (AG) . All
subclones of this tumor expressed high levels of the antigen recognized by this mAb .WARD ET AL .
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or otherspontaneous tumors includingthe one other spontaneoustumor that arose
in the same host as AG-104A did not react with the PW237 antibody. In addition,
autologous nonmalignant fibroblasts as well as other adult or embryonic fibroblasts
ofC3H origin or BALB/c origin were not recognized, while high levels of antigen
expression were detected on all subclones derived from the AG-104A tumor. We are
now in the process ofanalyzing themolecularnature ofthePW 237-defined antigen
and its relationship to the CTL-defined unique antigen(s) on the AG-104A tumor.
Discussion
In this study, we have generatedcloned immunologicalprobes that define individ-
ually distinct tumor antigens onUVinducedand spontaneoustumors . These probes
did not reactwith nonmalignant fibroblasts derived from the same host . CTL clones
andmAbs generated previously to putative unique tumor antigens (27, 29, 30) have
lacked critical controls required to exclude that similar antigens were widely expressed
on normal tissues of the autologous host . It might be considered trivial to require
that normal control cellsandDNA be obtained from the same host sincethe tumors
were induced in inbred mice . Presumably cells from syngeneic, i.e., genetically identical
hosts should be acceptable . While this is correct under idealized conditions, ex-
perimental practice has shown repeatedly that allogenicity canbe introduced insidi-
ously through errors that can occur during breeding (31) .
Allogenicity didnot influence the resultsof theearly tumortransplantation studies
ofchemically inducedtumors . These studies provided afirm basis for tumorimmu-
nology because (a) transplantation of autologous control tissues from the hosts of
tumor origin did not protect mice against challenge with autologous cancer cells
(3), and (6) immunity to tumors could be generated in the autologous host (4) . Fur-
thermore, allogenicity as acommon source of such transplantation antigens can be
excluded, because certain carcinogens induce strongly antigenic tumors at a very
high frequency (11), while with proper breeding precautions introduction of alloge-
nicity is a rare event . However, the generation of cloned immunological probes for
the transplantation antigens of MCA-induced tumors has been unsuccessful and
there are only rare instances in which transplantation antigens have been defined
with specific in vitro probes in other tumor models (27, 29, 30) . The difficulty in
generating cloned immunological probes may, therefore, have selected for excep-
tional tumors . In this paper, however, we show that individually distinct tumor an-
tigens canbe defined withCTL probes in themajority ofUV-induced regressortumors .
Previous studies have suggested that a single cancer cell can display multiple, in-
dependent, unique tumor antigens (27, 29) . Such antigens could be ideal targets
for combination therapy because the possibility that a cancer cell will lose several
independent antigens simultaneously is likely to be remote . However, allogenicity
resulting from multiple, unlinked, contaminating genes may mimic such multiple
unique tumorantigens . We, therefore, re-examined thepossibility that asingle cancer
cell canexpress several unique, independent antigens using a tumormodel forwhich
autologous control cells were available . Indeed, we find that a single tumor cell can
express at least two tumor antigens, both of which are uniquely expressed on the
particulartumortested butlost independentlyofeach otherupon immune selection .
In agreementwith previous studiesusingtransplantation assays (32, 33), ourcloned
in vitro probes demonstrate a very large diversity of unique tumor antigens on ex-228 TUMOR ANTIGENS DEFINED BY CLONED IMMUNOLOGICAL PROBES
perimentally induced and spontaneoustumors. Our presentexperiments do notde-
termine conclusively whether the CTL-defined antigens are responsible for trans-
plantation resistance andwhether CTLareessential for tumorrejection. Nevertheless,
we have shown previously that progressor variants can be selected in vitro using
cytolytic T cell clones (34), and by this method ofin vitro selectionwe have recently
found that at least some ofthe unique antigens defined here by in vitro CTL probes
appear also to be the targetsof tumorrejection in vivo (Ward, P L., and H. Schreiber,
unpublished observations). In addition, several progressor variants that arose in vivo
were found to have lost aCTL-defined antigen upon analysis in vitro (Ward, P. L.,
and H. Schreiber, unpublished observations). Thus, loss of a CTL-defined antigen
appears to correlate in several instances with tumor progression in vivo and the an-
tigens defined by transplantation assays andby CTL clones may, therefore, be closely
related.
It should be acknowledged that there is no evidence that the antigens described
here are truly tumor specific in the sense that each is encoded by a tumor-specific
mutant gene. If the antigens are not the result of somatic mutations, then they are
normal antigens, either syngeneic or allogeneic. Neitherthis studynorprevious studies
have excluded the possibility that these antigens are expressed on normal cells. In
the previous studies(35, 36), anonmalignant fibroblast line was cloned and expanded,
andthe subclones were malignantly transformed. Immunological analyses indicated
that all transformants had individually distinct antigens even though all tumors had
been derived from the same precursor cell. These experiments seemed to indicate
that the appearance of the antigens followed the exposure to carcinogen and that
these are new antigens, i.e., "neoantigens" that were not previously expressed on the
normal precursor cell. However, normal cells can generate considerable diversity
of surface molecules during clonal expansion from a single precursor (37, 38) and
the transformation event caused by the carcinogen may simply fix a particular anti-
genic phenotype (39). Alternatively, it is possible that normal previously nonexpressed
genes are randomly activated by the carcinogen (40). Obviously, both mechanisms
could produce considerable antigenicdiversitywith apparent tumorspecificity even
though these antigens are expressed in normal cells.
By the use of autologous normal fibroblasts as control target cells, our experi-
ments make it unlikely that the tumor antigens defined here by CTL probes are
widely expressedon normal tissues andrecognized by thehost as a result of residual
heterozygosity. However, we did nottest theexactautologous normal tissue counter-
part of the tumor, or better still, the particular normal cell that underwent malig-
nant transformation and gave rise to the particular tumor. Therefore, our experi-
ments cannot exclude that these CTL probes recognized normal tissue-specific
differentiation antigens or normal, clonally restricted antigens. However, if these
antigens representednormal tissue-specificdifferentiation antigens they wouldhave
to be highly polymorphic to account for the observed diversity of the CTL-defined
antigens on tumors of similar differentiation type. Our experiments showed that
three CTL clones (Fig. 5) did not crossreact with autologous control tumor cells
that were ofthe same histologic type and arose as second or third independent tumors
in the same animals. These findings do notsupport thenotion that such CTL-defined
antigens are recognized as tissue-specific antigens because ofresidual heterozygosity,
even though this possibility is not excluded. Even more difficult to exclude is theWARD ET AL.
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possibility that these antigens are found on a clonally restricted population of non-
malignant cells because cells expressing this antigen may not be found even after
extensive testing (41). Together, ourexperiments cannot provethat theso-calledtumor-
specific antigens are tumor specific in the strictest sense, since they might be en-
coded by normal genesand couldbe expressed on an unrecognized normal cell popu-
lation. On the other hand, there are new methods to use the cloned CTL (42, 43)
or antibody probes (44) for identifying the genes that encode the antigens defined
by these probes. The tools (tumors, immunological probes, and autologous control
cells and DNA), are now available to answer conclusively whether these antigens
are encoded by normal genes, or are truly tumor specific in that they are encoded
by tumor-specific mutant genes.
Experimental cancers are often considered laboratory curiosities because of the
large doses of carcinogens used to induce these cancers (28). The unique tumor an-
tigens expressed on these cancersmay not be representative ofhumancancer which
may be induced by lower doses of carcinogens. Some investigators, therefore, con-
sider "spontaneous" cancers of mice that arise without any known experimental in-
tervention as the most appropriatemodel of human cancer (28). Since spontaneous
murine cancers have been found by several investigators to be very poorly immuno-
genic by transplantation assays (2, 3), this might imply that human cancers also
do not express tumor-specific target antigens useful for diagnosis and therapy. In
fact, it has been suggested that the previously reported immunogenicity of sponta-
neous tumors mayhave been caused by residual heterozygosity in the inbred animal
strains (45), since after more generations of inbreeding spontaneous tumors were
found to be much less immunogenic (46). However, our experiments clearly indi-
cate that an individually distinct tumor antigen can be expressed on a spontaneous
cancer in acontrolled tumormodel where the antigen is not detected on autologous
normal fibroblasts or on a second cancer isolated from the same host. Our results
are consistent with the early studies that demonstrated the presence of individually
distinct antigens on several spontaneous tumors by transplantation assays (47-49).
Even though the spontaneous tumors were much less immunogenic than UVinduced
tumors, our results strongly suggest that spontaneous cancers in mice can express
unique tumor antigens.
Summary
We have isolated UV light-induced and spontaneoustumors along with nonmalig-
nant cells and tissues from each host. CD8+ CTL clones generated to a number
of highly immunogenic UV-induced tumors did not react with autologous normal
fibroblasts nor with autologous second tumors. Using up to 25 independently in-
duced tumors as targets, these CTL clones were found to be uniquely specific for
the particular tumor used for immunization even when multiple tumors isolated
from the same animals were used as targets. In addition to this extensive antigenic
diversity of independently induced tumors, we found that a single cancer cell can
express multiple independent antigens that were uniquely expressed on the tumor
butwere notdetectable on autologous nonmalignant fibroblasts. A poorly immuno-
genic spontaneous tumor was also found to express an antigen that was uniquely
specific forthe immunizing tumorin that it was absent from anyof 25 othertumors230 TUMOR ANTIGENS DEFINED BY CLONED IMMUNOLOGICAL PROBES
tested. This antigen was recognized by a mAb and not detected on autologous non-
malignant fibroblasts or on an autologous second spontaneous tumor. These findings
demonstrate that syngeneic CTL clones or mAbs can define unique antigens on UV
induced or spontaneous tumors. The use of autologous nonmalignant fibroblast targets
made it unlikely that these antigens were widely expressed on normal cells. The avail-
ability of cloned immunological probes to antigens on tumors isolated with autolo-
gous normal cells will allow a reliable identification ofthe genetic origins of unique
antigens on experimentally induced and spontaneous tumors and permit a decisive
answer to whether these unique antigens are encoded by normal genes or by genes
that have undergone somatic mutations; i.e., whether theseantigens are truly tumor
specific.
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